Qiagen N.V. $QGEN Shares Bought by Signaturefd LLC

Signaturefd LLC raised its position in Qiagen N.V. (NYSE:QGEN) by 23.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,132 shares of the company’s stock after purchasing an additional 778 shares during the quarter. Signaturefd LLC’s holdings in Qiagen were worth $199,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in shares of Qiagen by 12.2% in the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock valued at $972,191,000 after purchasing an additional 2,656,136 shares during the period. Deutsche Bank AG increased its stake in shares of Qiagen by 57.5% in the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock valued at $180,319,000 after purchasing an additional 1,639,621 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Qiagen by 3,030.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company’s stock valued at $179,501,000 after purchasing an additional 4,327,934 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Qiagen by 4.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company’s stock valued at $96,605,000 after purchasing an additional 109,481 shares during the period. Finally, Caisse Des Depots ET Consignations increased its stake in shares of Qiagen by 7.3% in the first quarter. Caisse Des Depots ET Consignations now owns 1,345,657 shares of the company’s stock valued at $53,374,000 after purchasing an additional 91,357 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Trading Down 0.1%

Shares of NYSE:QGEN opened at $46.26 on Friday. The stock has a market capitalization of $10.28 billion, a price-to-earnings ratio of 27.33, a PEG ratio of 2.44 and a beta of 0.66. Qiagen N.V. has a 1-year low of $37.63 and a 1-year high of $51.88. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The company has a 50 day moving average price of $47.53 and a 200 day moving average price of $45.19.

Qiagen (NYSE:QGEN) last issued its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analysts’ expectations of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period last year, the firm posted $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on QGEN shares. Barclays set a $53.00 price objective on shares of Qiagen and gave the company an “overweight” rating in a report on Thursday. Bank of America increased their price objective on shares of Qiagen from $50.00 to $53.00 and gave the company a “buy” rating in a report on Thursday, June 26th. Cowen reiterated a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Wall Street Zen cut shares of Qiagen from a “strong-buy” rating to a “buy” rating in a report on Monday, August 11th. Finally, UBS Group increased their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average target price of $49.40.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.